Pune, India | September 16, 2025
Biocon Biologics has received U.S. FDA approval for Jobevne™ (bevacizumab-nwgd), a biosimilar to the well-known cancer drug Avastin®. This approval is a significant advancement for Biocon’s oncology portfolio and supports its goal of delivering cost-effective, high-quality biologics to patients globally. With this milestone, Biocon now has seven biosimilars approved in the U.S.
Jobevne functions by targeting vascular endothelial growth factor (VEGF), a protein that supports tumor growth by forming new blood vessels. As a result, by blocking VEGF, the drug cuts off the tumor’s blood supply, helping to slow its progression. Biocon demonstrated Jobevne’s equivalence to Avastin through extensive clinical trials, which compared structural characteristics, pharmacokinetics, effectiveness, safety, and immune response. Consequently, these trials met the FDA’s strict criteria, confirming Jobevne’s clinical parity with Avastin.
The FDA has approved Jobevne for several cancer types, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and various forms of ovarian and peritoneal cancer. However, its use in adjuvant treatment of colon cancer is not included in the approval. Nevertheless, Jobevne’s broad range of indications enhances its potential role in oncology care, offering more choices for physicians and patients at lower costs.
Biocon Biologics already sells bevacizumab under the brand Abevmy in Europe and Canada. Now, with the U.S. launch, the approval of Jobevne significantly extends its global reach and strengthens its oncology offerings. Bevacizumab brought in nearly $2 billion in U.S. sales in 2023, suggesting that Jobevne could help reduce treatment expenses, improve access, and lessen the financial burden on both patients and healthcare systems.
Shreehas Tambe, CEO and Managing Director of Biocon Biologics, described the approval as “a significant milestone.” He noted that it highlights Biocon’s scientific strength and reinforces its long-term dedication to making advanced biologic treatments more accessible. In addition, according to Tambe, Jobevne’s success further validates Biocon’s capabilities in developing and delivering complex biologics worldwide.
This approval also underscores the growing credibility of biosimilars. Indeed, Biocon’s ability to navigate the stringent U.S. regulatory process showcases the maturity of the biosimilar sector. As a result, as more biosimilars enter the market, patients could benefit from greater access and reduced drug costs.
The announcement was well received by investors, with Biocon’s stock rising over 5%. Clearly, analysts view this FDA approval as an endorsement of Biocon’s biosimilar strategy and a promising indicator for its future growth. Currently, Biocon provides treatment to over five million patients annually and is developing 20 biosimilars across areas such as oncology, diabetes, and immunology.
Biocon Biologics now plans to accelerate Jobevne’s commercial rollout in the U.S. To achieve this, it aims to streamline manufacturing and distribution while collaborating with healthcare providers and insurers to support adoption. In the coming months, the market will reveal how Jobevne performs against other FDA-approved bevacizumab biosimilars.
In summary, Jobevne’s FDA approval is a key win for Biocon Biologics, expanding its footprint in the U.S. oncology space. More importantly, it brings the promise of affordable cancer treatments closer to reality for thousands of patients. With strong leadership, a deep pipeline, and a growing international presence, Biocon is reshaping the landscape of biologic medicines.
